CKD is developing non-hydroxamic acid (NHA)-based histone deacetylase 6 (HDAC6) inhibitors for non-oncology indications. CKD’s NHA inhibitors address the limitations of hydroxamic acid (HA ...
Tinostamustine is under clinical development by Mundipharma EDO and currently in Phase I for Mantle Cell Lymphoma.
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈